Center for Health Outcomes and Interdisciplinary Research, Department of Psychiatry, Massachusetts General Hospital, 1 Bowdoin Sq, Boston, MA, 02114, USA.
Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
J Neurooncol. 2023 Jul;163(3):707-716. doi: 10.1007/s11060-023-04389-1. Epub 2023 Jul 13.
To test the effects of the Relaxation Response Resiliency Program - Neurofibromatosis (3RP-NF), a mind-body resilience program for people with NF, on resilience factors from baseline to post-treatment and 6- and 12-month follow-up.
This is a secondary analysis of a fully powered randomized clinical trial (RCT) of 3RP-NF and health education control (HEP-NF). We recruited adults with NF1, NF2, or schwannomatosis who reported stress or difficulty coping with NF symptoms. Both conditions received 8 weekly 90-minute group sessions; 3RP-NF focused on building resilience skills. We measured resilience factors via the Measure of Current Status-A (adaptive coping), Cognitive and Affective Mindfulness Scale-Revised (mindfulness), Gratitude Questionnaire-6 (gratitude), Life Orientation Test Optimism Scale (optimism), and Medical Outcomes Study Social Support Survey (perceived social support) at baseline, post-intervention, and 6- and 12-month follow-up. We used linear mixed models with completely unstructured covariance across up to four repeated measurements (baseline, post-treatment, and 6- and 12-month follow-up) to investigate treatment effects on resilience factors.
We enrolled 228 individuals (M=42.7, SD = 14.6; 74.5% female; 87.7% White; 72.8% NF1, 14.0% NF2, 13.2% schwannomatosis). Within groups, both 3RP-NF and HEP-NF showed statistically significant improvements in all outcomes across timepoints. 3RP-NF showed significantly greater improvement in adaptive coping compared to HEP-NF from baseline to post-intervention and baseline to 6 months (M= 0.29; 95% CI 0.13-0.46; p < 0.001; M= 0.25; 95% CI 0.07-0.33; p = 0.005); there were no other between-group differences amongst the remaining resilience factors.
3RP-NF showed promise in sustainably improving coping abilities amongst people with NF.
ClinicalTrials.gov Identifier: NCT03406208. Registration submitted December 6, 2017, first patient enrolled October 2017.
测试针对 NF 患者的身心弹性恢复计划——多发性神经纤维瘤（3RP-NF）对弹性因素的影响，该计划是一项针对 NF 患者的身心弹性恢复计划，旨在从基线到治疗后以及 6 个月和 12 个月的随访期间测试弹性因素。
这是对 3RP-NF 和健康教育对照（HEP-NF）的完全有力的随机临床试验（RCT）的二次分析。我们招募了报告压力或难以应对 NF 症状的 NF1、NF2 或 schwannomatosis 成人。两种情况均接受 8 周每周 90 分钟的小组会议；3RP-NF 专注于建立弹性技能。我们通过当前状态量表 A（适应性应对）、认知和情感正念量表修订版（正念）、感恩问卷 6（感恩）、生活取向测试乐观量表（乐观）和医疗结果研究社会支持调查（感知社会支持）在基线、干预后以及 6 个月和 12 个月的随访中测量弹性因素。我们使用具有完全非结构化协方差的线性混合模型，最多可对四个重复测量（基线、治疗后以及 6 个月和 12 个月的随访）进行分析，以研究治疗对弹性因素的影响。
我们招募了 228 名个体（M=42.7，SD=14.6；74.5%女性；87.7%白人；72.8% NF1，14.0% NF2，13.2% schwannomatosis）。在组内，3RP-NF 和 HEP-NF 均在所有时间点的所有结果上均显示出统计学上的显著改善。与 HEP-NF 相比，3RP-NF 从基线到干预后以及从基线到 6 个月的适应性应对能力有显著改善（M=0.29；95%CI 0.13-0.46；p<0.001；M=0.25；95%CI 0.07-0.33；p=0.005）；在其余的弹性因素中，两组之间没有其他差异。
3RP-NF 显示出在可持续改善 NF 患者应对能力方面的前景。
ClinicalTrials.gov 标识符：NCT03406208。注册提交于 2017 年 12 月 6 日，首位患者于 2017 年 10 月入组。
